Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | IDO1 | P14902 | 4/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | CRHBP | P24387 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.40 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.40 |
| ▸ | SLC22A3 | O75751 | 1/20 | 0.40 |
| ▸ | PLAU | P00749 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | NOS1 | P29475 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4719357 | 1.00 | ALDH1A1 (0.49) | ALDH1A1RAB9AIDO1MAPTCRHBP | |
| SCHEMBL13218120 | 1.00 | ALDH1A1 (0.49) | ALDH1A1RAB9AIDO1MAPTCRHBP | |
| Hydrochloric Acid SCHEMBL11876930 | 0.98 | ALDH1A1 (0.47) | ALDH1A1RAB9AIDO1MAPTCRHBP | |
| SCHEMBL838151 | 0.80 | CA2 (0.56) | ALDH1A1IDO1TAAR1KMT2AL3MBTL1 | |
| SCHEMBL16697881 | 0.79 | TAAR1 (0.48) | ALDH1A1RAB9AIDO1HTR2ATAAR1 | |
| SCHEMBL16697877 | 0.79 | TAAR1 (0.48) | ALDH1A1RAB9AIDO1HTR2ATAAR1 | |
| SCHEMBL14827527 | 0.78 | CTBP2 (0.53) | ALDH1A1IDO1MAPTHTTTAAR1 | |
| SCHEMBL5673911 | 0.78 | CYP3A4 (0.40) | ALDH1A1IDO1MAPTHTTSLC22A2 | |
| SCHEMBL103073 | 0.78 | CTBP2 (0.53) | ALDH1A1RAB9AIDO1TAAR1SLC22A2 | |
| SCHEMBL103072 | 0.78 | CTBP2 (0.53) | ALDH1A1RAB9AIDO1TAAR1SLC22A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1216230-B1 | FUSED CYCLOHEPTANE AND FUSED AZACYCLOHEPTANE COMPOUNDS AND THEIR USE AS INTEGRIN RECEPTOR ANTAGONISTS | AMGEN INC (US) | 2008-04-23 | — | — | EP | disclosed |
| EP-1339710-B1 | 3-OXADIAZOL-5-YL-1-AMINOALKYL-1H-INDOLE DERIVATIVES | AMRAD OPERATIONS PTY LTD (AU) | 2006-03-01 | — | — | EP | disclosed |
| US-6930118-B2 | 3-Oxadiazol-5-yl-1-aminoalkyl-1h-indole derivatives | AMRAD OPERATIONS PTY. LTD. (AU) | 2005-08-16 | — | — | US | disclosed |
| EP-1339710-A4 | 3-OXADIAZOL-5-YL-1-AMINOALKYL-1H-INDOLE DERIVATIVES | AMRAD OPERATIONS PTY LTD (AU) | 2004-05-12 | — | — | EP | disclosed |
| US-20040034073-A1 | 3-Oxadiazol-5-yl-1-aminoalkyl-1h-indole derivatives | AMRAD OPERATIONS PTY. LTD. (AU) | 2004-02-19 | — | — | US | disclosed |
| EP-1339710-A1 | 3-OXADIAZOL-5-YL-1-AMINOALKYL-1H-INDOLE DERIVATIVES | Amrad Operations Pty.,Ltd. (AU) | 2003-09-03 | — | — | EP | disclosed |
| US-6514964-B1 | Treating diseases, conditions or disorders mediated by integrin receptors, such as vitronectin and fibronectin receptors | AMGEN INC. | 2003-02-04 | — | — | US | disclosed |
| EP-1216230-A2 | FUSED CYCLOHEPTANE AND FUSED AZACYCLOHEPTANE COMPOUNDS AND THEIR USE AS INTEGRIN RECEPTOR ANTAGONISTS | Amgen Inc. (US) | 2002-06-26 | — | — | EP | disclosed |
| WO-2002036590-A1 | 3-OXADIAZOL-5-YL-1-AMINOALKYL-1H-INDOLE DERIVATIVES | AMRAD OPERATIONS PTY LTD (AU) | 2002-05-10 | — | — | WO | disclosed |
| WO-2001023357-A2 | FUSED CYCLOHEPTANE AND FUSED AZACYCLOHEPTANE COMPOUNDS AND THEIR USE AS INTEGRIN RECEPTOR ANTAGONISTS | AMGEN INC. (US) | 2001-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040034073-A1 | 3-Oxadiazol-5-yl-1-aminoalkyl-1h-indole derivatives | CNR1, CNR2, OPRK1 | ALDH1A1 497/4885RAB9A 2178/4885IDO1 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.